PMC:7200337 / 74073-75250 JSONTXT

Annnotations TAB JSON ListView MergeView

    LitCovid-PD-FMA-UBERON

    {"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T657","span":{"begin":349,"end":358},"obj":"Body_part"},{"id":"T658","span":{"begin":455,"end":464},"obj":"Body_part"},{"id":"T659","span":{"begin":513,"end":516},"obj":"Body_part"},{"id":"T660","span":{"begin":622,"end":630},"obj":"Body_part"},{"id":"T661","span":{"begin":632,"end":641},"obj":"Body_part"},{"id":"T662","span":{"begin":743,"end":746},"obj":"Body_part"},{"id":"T663","span":{"begin":798,"end":807},"obj":"Body_part"},{"id":"T664","span":{"begin":812,"end":823},"obj":"Body_part"},{"id":"T665","span":{"begin":1001,"end":1007},"obj":"Body_part"},{"id":"T666","span":{"begin":1045,"end":1048},"obj":"Body_part"},{"id":"T667","span":{"begin":1050,"end":1061},"obj":"Body_part"},{"id":"T668","span":{"begin":1062,"end":1072},"obj":"Body_part"},{"id":"T669","span":{"begin":1148,"end":1151},"obj":"Body_part"},{"id":"T670","span":{"begin":1162,"end":1165},"obj":"Body_part"}],"attributes":[{"id":"A657","pred":"fma_id","subj":"T657","obj":"http://purl.org/sig/ont/fma/fma63836"},{"id":"A658","pred":"fma_id","subj":"T658","obj":"http://purl.org/sig/ont/fma/fma63836"},{"id":"A659","pred":"fma_id","subj":"T659","obj":"http://purl.org/sig/ont/fma/fma84079"},{"id":"A660","pred":"fma_id","subj":"T660","obj":"http://purl.org/sig/ont/fma/fma84050"},{"id":"A661","pred":"fma_id","subj":"T661","obj":"http://purl.org/sig/ont/fma/fma241981"},{"id":"A662","pred":"fma_id","subj":"T662","obj":"http://purl.org/sig/ont/fma/fma20935"},{"id":"A663","pred":"fma_id","subj":"T663","obj":"http://purl.org/sig/ont/fma/fma62864"},{"id":"A664","pred":"fma_id","subj":"T664","obj":"http://purl.org/sig/ont/fma/fma63261"},{"id":"A665","pred":"fma_id","subj":"T665","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A666","pred":"fma_id","subj":"T666","obj":"http://purl.org/sig/ont/fma/fma20935"},{"id":"A667","pred":"fma_id","subj":"T667","obj":"http://purl.org/sig/ont/fma/fma62854"},{"id":"A668","pred":"fma_id","subj":"T668","obj":"http://purl.org/sig/ont/fma/fma63261"},{"id":"A669","pred":"fma_id","subj":"T669","obj":"http://purl.org/sig/ont/fma/fma67095"},{"id":"A670","pred":"fma_id","subj":"T670","obj":"http://purl.org/sig/ont/fma/fma67095"}],"text":"Available Therapeutic Options to Manage COVID-19 Immunopathology and to Deter Viral Propagation\n(A) Rdrp inhibitors (remdesivir, favipiravir), protease inhibitors (lopinavir/ritonavir), and antifusion inhibitors (arbidol) are currently being investigated in their efficacy in controlling SARS-CoV-2 infections.\n(B) CQ and HCQ increase the pH within lysosomes, impairing viral transit through the endolysosomal pathway. Reduced proteolytic function within lysosomes augments antigen processing for presentation on MHC complexes and increases CTLA4 expression on Tregs.\n(C) Antagonism of IL-6 signaling pathway and of other cytokine-/chemokine-associated targets has been proposed to control COVID-19 CRS. These include secreted factors like GM-CSF that contribute to the recruitment of inflammatory monocytes and macrophages.\n(D) Several potential sources of SARS-CoV-2 neutralizing antibodies are currently under investigation, including monoclonal antibodies, polyclonal antibodies, and convalescent plasma from recovered COVID-19 patients.\nGM-CSF, granulocyte-macrophage colony-stimulating factor; CQ, chloroquine; HCQ, hydroxychloroquine; RdRp, RNA-dependent RNA polymerase."}

    LitCovid-PD-MONDO

    {"project":"LitCovid-PD-MONDO","denotations":[{"id":"T442","span":{"begin":40,"end":48},"obj":"Disease"},{"id":"T443","span":{"begin":288,"end":296},"obj":"Disease"},{"id":"T444","span":{"begin":299,"end":309},"obj":"Disease"},{"id":"T445","span":{"begin":690,"end":698},"obj":"Disease"},{"id":"T446","span":{"begin":699,"end":702},"obj":"Disease"},{"id":"T448","span":{"begin":858,"end":866},"obj":"Disease"},{"id":"T449","span":{"begin":1023,"end":1031},"obj":"Disease"}],"attributes":[{"id":"A442","pred":"mondo_id","subj":"T442","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A443","pred":"mondo_id","subj":"T443","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A444","pred":"mondo_id","subj":"T444","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A445","pred":"mondo_id","subj":"T445","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A446","pred":"mondo_id","subj":"T446","obj":"http://purl.obolibrary.org/obo/MONDO_0007399"},{"id":"A447","pred":"mondo_id","subj":"T446","obj":"http://purl.obolibrary.org/obo/MONDO_0017361"},{"id":"A448","pred":"mondo_id","subj":"T448","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A449","pred":"mondo_id","subj":"T449","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Available Therapeutic Options to Manage COVID-19 Immunopathology and to Deter Viral Propagation\n(A) Rdrp inhibitors (remdesivir, favipiravir), protease inhibitors (lopinavir/ritonavir), and antifusion inhibitors (arbidol) are currently being investigated in their efficacy in controlling SARS-CoV-2 infections.\n(B) CQ and HCQ increase the pH within lysosomes, impairing viral transit through the endolysosomal pathway. Reduced proteolytic function within lysosomes augments antigen processing for presentation on MHC complexes and increases CTLA4 expression on Tregs.\n(C) Antagonism of IL-6 signaling pathway and of other cytokine-/chemokine-associated targets has been proposed to control COVID-19 CRS. These include secreted factors like GM-CSF that contribute to the recruitment of inflammatory monocytes and macrophages.\n(D) Several potential sources of SARS-CoV-2 neutralizing antibodies are currently under investigation, including monoclonal antibodies, polyclonal antibodies, and convalescent plasma from recovered COVID-19 patients.\nGM-CSF, granulocyte-macrophage colony-stimulating factor; CQ, chloroquine; HCQ, hydroxychloroquine; RdRp, RNA-dependent RNA polymerase."}

    LitCovid-PD-CLO

    {"project":"LitCovid-PD-CLO","denotations":[{"id":"T842","span":{"begin":97,"end":98},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T843","span":{"begin":312,"end":313},"obj":"http://purl.obolibrary.org/obo/CLO_0001021"},{"id":"T844","span":{"begin":349,"end":358},"obj":"http://purl.obolibrary.org/obo/GO_0005764"},{"id":"T845","span":{"begin":455,"end":464},"obj":"http://purl.obolibrary.org/obo/GO_0005764"},{"id":"T846","span":{"begin":541,"end":546},"obj":"http://purl.obolibrary.org/obo/PR_000001852"},{"id":"T847","span":{"begin":561,"end":566},"obj":"http://purl.obolibrary.org/obo/CL_0000792"},{"id":"T848","span":{"begin":591,"end":600},"obj":"http://purl.obolibrary.org/obo/SO_0000418"},{"id":"T849","span":{"begin":661,"end":664},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T850","span":{"begin":798,"end":807},"obj":"http://purl.obolibrary.org/obo/CL_0000576"},{"id":"T851","span":{"begin":1001,"end":1007},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"}],"text":"Available Therapeutic Options to Manage COVID-19 Immunopathology and to Deter Viral Propagation\n(A) Rdrp inhibitors (remdesivir, favipiravir), protease inhibitors (lopinavir/ritonavir), and antifusion inhibitors (arbidol) are currently being investigated in their efficacy in controlling SARS-CoV-2 infections.\n(B) CQ and HCQ increase the pH within lysosomes, impairing viral transit through the endolysosomal pathway. Reduced proteolytic function within lysosomes augments antigen processing for presentation on MHC complexes and increases CTLA4 expression on Tregs.\n(C) Antagonism of IL-6 signaling pathway and of other cytokine-/chemokine-associated targets has been proposed to control COVID-19 CRS. These include secreted factors like GM-CSF that contribute to the recruitment of inflammatory monocytes and macrophages.\n(D) Several potential sources of SARS-CoV-2 neutralizing antibodies are currently under investigation, including monoclonal antibodies, polyclonal antibodies, and convalescent plasma from recovered COVID-19 patients.\nGM-CSF, granulocyte-macrophage colony-stimulating factor; CQ, chloroquine; HCQ, hydroxychloroquine; RdRp, RNA-dependent RNA polymerase."}

    LitCovid-PD-CHEBI

    {"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T77021","span":{"begin":33,"end":39},"obj":"Chemical"},{"id":"T60495","span":{"begin":105,"end":115},"obj":"Chemical"},{"id":"T73210","span":{"begin":117,"end":127},"obj":"Chemical"},{"id":"T70894","span":{"begin":129,"end":140},"obj":"Chemical"},{"id":"T89954","span":{"begin":143,"end":162},"obj":"Chemical"},{"id":"T54802","span":{"begin":152,"end":162},"obj":"Chemical"},{"id":"T15191","span":{"begin":164,"end":183},"obj":"Chemical"},{"id":"T82677","span":{"begin":164,"end":173},"obj":"Chemical"},{"id":"T88539","span":{"begin":174,"end":183},"obj":"Chemical"},{"id":"T33657","span":{"begin":201,"end":211},"obj":"Chemical"},{"id":"T6138","span":{"begin":213,"end":220},"obj":"Chemical"},{"id":"T69396","span":{"begin":315,"end":317},"obj":"Chemical"},{"id":"T38298","span":{"begin":474,"end":481},"obj":"Chemical"},{"id":"T180","span":{"begin":586,"end":588},"obj":"Chemical"},{"id":"T182","span":{"begin":740,"end":742},"obj":"Chemical"},{"id":"T74683","span":{"begin":1042,"end":1044},"obj":"Chemical"},{"id":"T184","span":{"begin":1100,"end":1102},"obj":"Chemical"},{"id":"T86587","span":{"begin":1104,"end":1115},"obj":"Chemical"},{"id":"T186","span":{"begin":1122,"end":1140},"obj":"Chemical"}],"attributes":[{"id":"A60430","pred":"chebi_id","subj":"T77021","obj":"http://purl.obolibrary.org/obo/CHEBI_81767"},{"id":"A68727","pred":"chebi_id","subj":"T60495","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A36931","pred":"chebi_id","subj":"T73210","obj":"http://purl.obolibrary.org/obo/CHEBI_145994"},{"id":"A51229","pred":"chebi_id","subj":"T70894","obj":"http://purl.obolibrary.org/obo/CHEBI_134722"},{"id":"A66000","pred":"chebi_id","subj":"T89954","obj":"http://purl.obolibrary.org/obo/CHEBI_37670"},{"id":"A64868","pred":"chebi_id","subj":"T89954","obj":"http://purl.obolibrary.org/obo/CHEBI_60258"},{"id":"A24317","pred":"chebi_id","subj":"T54802","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A59362","pred":"chebi_id","subj":"T15191","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A52098","pred":"chebi_id","subj":"T82677","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A11386","pred":"chebi_id","subj":"T88539","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A86167","pred":"chebi_id","subj":"T33657","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A83638","pred":"chebi_id","subj":"T6138","obj":"http://purl.obolibrary.org/obo/CHEBI_134730"},{"id":"A14293","pred":"chebi_id","subj":"T69396","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A3113","pred":"chebi_id","subj":"T38298","obj":"http://purl.obolibrary.org/obo/CHEBI_59132"},{"id":"A41394","pred":"chebi_id","subj":"T180","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A7965","pred":"chebi_id","subj":"T180","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A95575","pred":"chebi_id","subj":"T182","obj":"http://purl.obolibrary.org/obo/CHEBI_74120"},{"id":"A41049","pred":"chebi_id","subj":"T74683","obj":"http://purl.obolibrary.org/obo/CHEBI_74120"},{"id":"A81090","pred":"chebi_id","subj":"T184","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A37502","pred":"chebi_id","subj":"T86587","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A40845","pred":"chebi_id","subj":"T186","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"}],"text":"Available Therapeutic Options to Manage COVID-19 Immunopathology and to Deter Viral Propagation\n(A) Rdrp inhibitors (remdesivir, favipiravir), protease inhibitors (lopinavir/ritonavir), and antifusion inhibitors (arbidol) are currently being investigated in their efficacy in controlling SARS-CoV-2 infections.\n(B) CQ and HCQ increase the pH within lysosomes, impairing viral transit through the endolysosomal pathway. Reduced proteolytic function within lysosomes augments antigen processing for presentation on MHC complexes and increases CTLA4 expression on Tregs.\n(C) Antagonism of IL-6 signaling pathway and of other cytokine-/chemokine-associated targets has been proposed to control COVID-19 CRS. These include secreted factors like GM-CSF that contribute to the recruitment of inflammatory monocytes and macrophages.\n(D) Several potential sources of SARS-CoV-2 neutralizing antibodies are currently under investigation, including monoclonal antibodies, polyclonal antibodies, and convalescent plasma from recovered COVID-19 patients.\nGM-CSF, granulocyte-macrophage colony-stimulating factor; CQ, chloroquine; HCQ, hydroxychloroquine; RdRp, RNA-dependent RNA polymerase."}

    LitCovid-PD-GO-BP

    {"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T189","span":{"begin":474,"end":492},"obj":"http://purl.obolibrary.org/obo/GO_0019882"},{"id":"T190","span":{"begin":591,"end":608},"obj":"http://purl.obolibrary.org/obo/GO_0007165"},{"id":"T191","span":{"begin":591,"end":600},"obj":"http://purl.obolibrary.org/obo/GO_0023052"}],"text":"Available Therapeutic Options to Manage COVID-19 Immunopathology and to Deter Viral Propagation\n(A) Rdrp inhibitors (remdesivir, favipiravir), protease inhibitors (lopinavir/ritonavir), and antifusion inhibitors (arbidol) are currently being investigated in their efficacy in controlling SARS-CoV-2 infections.\n(B) CQ and HCQ increase the pH within lysosomes, impairing viral transit through the endolysosomal pathway. Reduced proteolytic function within lysosomes augments antigen processing for presentation on MHC complexes and increases CTLA4 expression on Tregs.\n(C) Antagonism of IL-6 signaling pathway and of other cytokine-/chemokine-associated targets has been proposed to control COVID-19 CRS. These include secreted factors like GM-CSF that contribute to the recruitment of inflammatory monocytes and macrophages.\n(D) Several potential sources of SARS-CoV-2 neutralizing antibodies are currently under investigation, including monoclonal antibodies, polyclonal antibodies, and convalescent plasma from recovered COVID-19 patients.\nGM-CSF, granulocyte-macrophage colony-stimulating factor; CQ, chloroquine; HCQ, hydroxychloroquine; RdRp, RNA-dependent RNA polymerase."}

    LitCovid-PubTator

    {"project":"LitCovid-PubTator","denotations":[{"id":"2341","span":{"begin":69,"end":71},"obj":"Gene"},{"id":"2342","span":{"begin":30,"end":32},"obj":"Gene"},{"id":"2343","span":{"begin":40,"end":48},"obj":"Disease"},{"id":"2349","span":{"begin":100,"end":104},"obj":"Gene"},{"id":"2350","span":{"begin":117,"end":127},"obj":"Chemical"},{"id":"2351","span":{"begin":129,"end":140},"obj":"Chemical"},{"id":"2352","span":{"begin":164,"end":183},"obj":"Chemical"},{"id":"2353","span":{"begin":288,"end":309},"obj":"Disease"},{"id":"2357","span":{"begin":541,"end":546},"obj":"Gene"},{"id":"2358","span":{"begin":315,"end":317},"obj":"Chemical"},{"id":"2359","span":{"begin":322,"end":325},"obj":"Chemical"},{"id":"2365","span":{"begin":586,"end":590},"obj":"Gene"},{"id":"2366","span":{"begin":740,"end":746},"obj":"Gene"},{"id":"2367","span":{"begin":763,"end":765},"obj":"Gene"},{"id":"2368","span":{"begin":679,"end":681},"obj":"Gene"},{"id":"2369","span":{"begin":690,"end":698},"obj":"Disease"},{"id":"2373","span":{"begin":1032,"end":1040},"obj":"Species"},{"id":"2374","span":{"begin":858,"end":868},"obj":"Species"},{"id":"2375","span":{"begin":1023,"end":1031},"obj":"Disease"},{"id":"2383","span":{"begin":1042,"end":1048},"obj":"Gene"},{"id":"2384","span":{"begin":1050,"end":1098},"obj":"Gene"},{"id":"2385","span":{"begin":1142,"end":1146},"obj":"Gene"},{"id":"2386","span":{"begin":1100,"end":1102},"obj":"Chemical"},{"id":"2387","span":{"begin":1104,"end":1115},"obj":"Chemical"},{"id":"2388","span":{"begin":1117,"end":1120},"obj":"Chemical"},{"id":"2389","span":{"begin":1122,"end":1140},"obj":"Chemical"}],"attributes":[{"id":"A2341","pred":"tao:has_database_id","subj":"2341","obj":"Gene:6999"},{"id":"A2342","pred":"tao:has_database_id","subj":"2342","obj":"Gene:6999"},{"id":"A2343","pred":"tao:has_database_id","subj":"2343","obj":"MESH:C000657245"},{"id":"A2349","pred":"tao:has_database_id","subj":"2349","obj":"Gene:43740578"},{"id":"A2350","pred":"tao:has_database_id","subj":"2350","obj":"MESH:C000606551"},{"id":"A2351","pred":"tao:has_database_id","subj":"2351","obj":"MESH:C462182"},{"id":"A2352","pred":"tao:has_database_id","subj":"2352","obj":"MESH:C558899"},{"id":"A2353","pred":"tao:has_database_id","subj":"2353","obj":"MESH:C000657245"},{"id":"A2357","pred":"tao:has_database_id","subj":"2357","obj":"Gene:1493"},{"id":"A2358","pred":"tao:has_database_id","subj":"2358","obj":"MESH:D002738"},{"id":"A2359","pred":"tao:has_database_id","subj":"2359","obj":"MESH:D006886"},{"id":"A2365","pred":"tao:has_database_id","subj":"2365","obj":"Gene:3569"},{"id":"A2366","pred":"tao:has_database_id","subj":"2366","obj":"Gene:1437"},{"id":"A2367","pred":"tao:has_database_id","subj":"2367","obj":"Gene:6999"},{"id":"A2368","pred":"tao:has_database_id","subj":"2368","obj":"Gene:6999"},{"id":"A2369","pred":"tao:has_database_id","subj":"2369","obj":"MESH:C000657245"},{"id":"A2373","pred":"tao:has_database_id","subj":"2373","obj":"Tax:9606"},{"id":"A2374","pred":"tao:has_database_id","subj":"2374","obj":"Tax:2697049"},{"id":"A2375","pred":"tao:has_database_id","subj":"2375","obj":"MESH:C000657245"},{"id":"A2383","pred":"tao:has_database_id","subj":"2383","obj":"Gene:1437"},{"id":"A2384","pred":"tao:has_database_id","subj":"2384","obj":"Gene:1437"},{"id":"A2385","pred":"tao:has_database_id","subj":"2385","obj":"Gene:43740578"},{"id":"A2386","pred":"tao:has_database_id","subj":"2386","obj":"MESH:D002738"},{"id":"A2387","pred":"tao:has_database_id","subj":"2387","obj":"MESH:D002738"},{"id":"A2388","pred":"tao:has_database_id","subj":"2388","obj":"MESH:D006886"},{"id":"A2389","pred":"tao:has_database_id","subj":"2389","obj":"MESH:D006886"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Available Therapeutic Options to Manage COVID-19 Immunopathology and to Deter Viral Propagation\n(A) Rdrp inhibitors (remdesivir, favipiravir), protease inhibitors (lopinavir/ritonavir), and antifusion inhibitors (arbidol) are currently being investigated in their efficacy in controlling SARS-CoV-2 infections.\n(B) CQ and HCQ increase the pH within lysosomes, impairing viral transit through the endolysosomal pathway. Reduced proteolytic function within lysosomes augments antigen processing for presentation on MHC complexes and increases CTLA4 expression on Tregs.\n(C) Antagonism of IL-6 signaling pathway and of other cytokine-/chemokine-associated targets has been proposed to control COVID-19 CRS. These include secreted factors like GM-CSF that contribute to the recruitment of inflammatory monocytes and macrophages.\n(D) Several potential sources of SARS-CoV-2 neutralizing antibodies are currently under investigation, including monoclonal antibodies, polyclonal antibodies, and convalescent plasma from recovered COVID-19 patients.\nGM-CSF, granulocyte-macrophage colony-stimulating factor; CQ, chloroquine; HCQ, hydroxychloroquine; RdRp, RNA-dependent RNA polymerase."}

    LitCovid-sentences

    {"project":"LitCovid-sentences","denotations":[{"id":"T417","span":{"begin":96,"end":310},"obj":"Sentence"},{"id":"T418","span":{"begin":311,"end":418},"obj":"Sentence"},{"id":"T419","span":{"begin":419,"end":567},"obj":"Sentence"},{"id":"T420","span":{"begin":568,"end":703},"obj":"Sentence"},{"id":"T421","span":{"begin":704,"end":824},"obj":"Sentence"},{"id":"T422","span":{"begin":825,"end":1041},"obj":"Sentence"},{"id":"T423","span":{"begin":1042,"end":1177},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Available Therapeutic Options to Manage COVID-19 Immunopathology and to Deter Viral Propagation\n(A) Rdrp inhibitors (remdesivir, favipiravir), protease inhibitors (lopinavir/ritonavir), and antifusion inhibitors (arbidol) are currently being investigated in their efficacy in controlling SARS-CoV-2 infections.\n(B) CQ and HCQ increase the pH within lysosomes, impairing viral transit through the endolysosomal pathway. Reduced proteolytic function within lysosomes augments antigen processing for presentation on MHC complexes and increases CTLA4 expression on Tregs.\n(C) Antagonism of IL-6 signaling pathway and of other cytokine-/chemokine-associated targets has been proposed to control COVID-19 CRS. These include secreted factors like GM-CSF that contribute to the recruitment of inflammatory monocytes and macrophages.\n(D) Several potential sources of SARS-CoV-2 neutralizing antibodies are currently under investigation, including monoclonal antibodies, polyclonal antibodies, and convalescent plasma from recovered COVID-19 patients.\nGM-CSF, granulocyte-macrophage colony-stimulating factor; CQ, chloroquine; HCQ, hydroxychloroquine; RdRp, RNA-dependent RNA polymerase."}